Big news that affects a lot of us - wanted to make sure everyone’s informed.
The Situation:
The FDA removed semaglutide from its drug shortage list in February 2025, which means compounding pharmacies can no longer make copies of commercially available GLP-1s.
Key Dates:
- 503A pharmacies deadline: April 22, 2025
- 503B outsourcing facilities deadline: May 22, 2025
What This Means:
If you’re on compounded semaglutide:
- Regular compounded versions are no longer allowed
- You may need to switch to brand name (Ozempic/Wegovy)
- Cost difference is significant ($200-400/mo vs $1,000+/mo)
Exceptions that still exist:
- Non-standard doses not commercially available
- Specific medical needs determined by your provider
- Compounded tirzepatide had similar restrictions
Legal Battles:
The Outsourcing Facilities Association sued the FDA, claiming the decision was “reckless and arbitrary.” Courts are still reviewing this.
What To Do:
- Talk to your provider about options
- Check your insurance coverage for brand versions
- Look into manufacturer savings programs
- Don’t panic - there are still paths forward
How is this affecting you? Share your experience below ![]()
Sources: FDA Drug Shortage Update, Pharmacy Times